Respiratory diseases in HIV-infected patients (review)
https://doi.org/10.22625/2072-6732-2020-12-4-5-18
Abstract
The review presents information on epidemiology, clinical, laboratory and radiological manifestations of infectious and malignant respiratory diseases in HIV-infected patients.
The data on the most common infections (communityacquired pneumonia, tuberculosis, Pneumocystis jiroveci pneumonia) and malignant diseases (Kaposhi’s sarcoma, lymphomas) as well as less frequent diseases (CMV-infection, MAC-infection, fungal pneumonias) are presented.
The article contains facts about the incidence of pulmonary diseases according to the severity of HIV-associated immunodeficiency. This review also presents current information on the diagnostic criteria, treatment regimens and secondary prophylaxis for HIV-associated respiratory infections and malignancies. The specialties of ART initiation in definite cases of opportunistic infections and ART assignment during the diagnostic period are highlighted.
The growing number of HIV-infected patients and the wide spectrum of possible pulmonary diseases argue the need for optimal clinical approach to HIV-infected patients with respiratory lesions for various physicians (general practitioners, pulmonologists and phthisiatricians).
About the Authors
I. B. Viktorova
Novokuznetsk state Institute for Further Training of Physicians – Branch Campus of Russian Medical Academy of Continuous Professional Education
Russian Federation
Novokuznetsk
Russian Federation
Novokuznetsk
V. N. Zimina
Peoples’ Friendship University of Russia
Russian Federation
Moscow
Russian Federation
Moscow
S. Yu. Degtyareva
Peoples’ Friendship University of Russia
Russian Federation
Moscow
Russian Federation
Moscow
A. V. Kravtchenko
Сentral Research Institute of Epidemiology
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Global AIDS monitoring 2018: indicators for monitoring the 2016 United Nations Political Declaration on HIV and AIDS. Geneva: UNAIDS; 2018 [Internet]. 2018. [Cited 23.08.2019] Available from: http://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf
2. Shakhgil’dian V.I. Struktura vtorichnyh zabolevanij i sovremennye pohody k ih laboratornoj diagnostike u bol’nyh VICH-infekciej / Shakhgil’dian V.I., Yadrikhinskaya M.S., Safonova A.P., Domonova E.A., Shipulina O.Yu., Al’vares Figeroa M.V., Dolgova E.A., Tishkevich O.A. // Epidemiologiya i infekcionnye bolezni. – 2015; T. 1. – S. 24–30. (in Russian).
3. Benito N, Rañó A, Moreno A, González J, Luna M, Agustí C, et al. Pulmonary Infiltrates in HIV-Infected Patients in the Highly Active Antiretroviral Therapy Era in Spain. JAIDS J Acquir Immune Defic Syndr [Internet]. 2001;27:35–43. [Cited 23.08.2019] Available from: https://journals.lww.com/jaids/Fulltext/2001/05010/Pulmonary_Infiltrates_in_HIV_Infected_Patients_in.6.aspx
4. Kohli R, Lo Y, Homel P, Flanigan TP, Gardner LI, Howard AA, et al. Bacterial Pneumonia, HIV Therapy, and Disease Progression among HIV-Infected Women in the HIV Epidemiologic Research (HER) Study. Clin Infect Dis. 2006;43(1):90–8.
5. Sullivan JH, Moore RD, Keruly JC, Chaisson RE. Effect of Antiretroviral Therapy on the Incidence of Bacterial Pneumonia in Patients with Advanced HIV Infection. 2000;162:64–7.
6. Cillóniz C, García-Vidal C, Moreno A, Miro JM, Torres A. Community-acquired bacterial pneumonia in adult HIV-infected patients. Expert Rev Anti Infect Ther [Internet]. 2018 Jul 3;16(7):579–88. [Cited 23.08.2019] Available from: https://doi.org/10.1080/14787210.2018.1495560
7. Gordin FM, Roediger MP, Girard PM, Lundgren JD, Miro JM, Palfreeman A, et al. Pneumonia in HIV-infected persons: Increased risk with cigarette smoking and treatment interruption. Am J Respir Crit Care Med. 2008;178(6):630–6.
8. Mane A, Gujar P, Gaikwad S, Bembalkar S, Gaikwad S, Dhamgaye T, et al. Aetiological spectrum of severe communityacquired pneumonia in HIV-positive patients from Pune, India. Indian J Med Res [Internet]. 2018 Feb;147(2):202–6. [Cited 04.07.2019] Available from: https://www.ncbi.nlm.nih.gov/pubmed/29806610
9. Saindou M, Chidiac C, Miailhes P, Voirin N, Baratin D, Amiri M, et al. Pneumococcal pneumonia in HIV-infected patients by antiretroviral therapy periods. HIV Med. 2008 Apr;9(4):203–7.
10. Cordero E, Pachon J, Rivero A, Giron JA, Gomez-Mateos J, Merino MD, et al. Haemophilus influenzae Pneumonia in Human Immunodeficiency Virus-Infected Patients. Clin Infect Dis. 2000;30(3):461–5.
11. Park DR, Sherbin VL, Goodman MS, Pacifico AD, Rubenfeld GD, Polissar NL, et al. The Etiology of Community‐Acquired Pneumonia at an Urban Public Hospital: Influence of Human Immunodeficiency Virus Infection and Initial Severity of Illness. J Infect Dis. 2001;184(3):268–77. doi: 10.1086/322040
12. Head BM, Trajtman A, Rueda Z V, V lez L, Keynan Y. Atypical bacterial pneumonia in the HIV-infected population. Pneumonia. 2017;9(12):1–7.
13. Sinclair A, Xie X, Teltscher M. Systematic Review and Meta-Analysis of a Urine-Based Pneumococcal Antigen Test for Diagnosis of Community-Acquired Pneumonia Caused by Streptococcus pneumoniae. J Clin Microbiol. 2013;51(7):2303–10.
14. Gatserelia L, Sharvadze L, Karchava M, Babridze N, Tsetvadze T, Dvali N, et al. Procalcitonin as a marker of bacterial sepsis in immunocompromised patients. Retrovirology [Internet]. 2012;9(Suppl 1):P90. [Cited 04.07.2019] Available from: http://www.retrovirology.com/content/9/S1/P90
15. Miku a T, Suchacz M, Sta czak W, Koz owska J, Wierci skaDrapa o A. Procalcitonin as a Biomarker of the Early Stage of Bacterial Infections in HIV/AIDS Patients. Eur J Inflamm. 2014 May 1;12(2):305–13. doi: org/10.1177/1721727X1401200210
16. Schleicher GK, Herbert V, Brink A, Martin S, Maraj R, Galpin JS, et al. Procalcitonin and C-reactive protein levels in HIV-positive subjects with tuberculosis and pneumonia. Eur Respir J. 2005 Apr;25(4):688–92.
17. Mendelson F, Griesel R, Tiffin N, Rangaka M, Boulle A, Mendelson M, et al. C-reactive protein and procalcitonin to discriminate between tuberculosis, Pneumocystis jirovecii pneumonia, and bacterial pneumonia in HIV-infected inpatients meeting WHO criteria for seriously ill: a prospective cohort study. BMC Infect Dis. 2018 Aug;18(1):399.
18. Swaminathan S, Padmapriyadarsini C, Narendran G. HIV-associated tuberculosis: clinical update. Clin Infect Dis. 2010 May;50(10):1377–86.
19. Zimina V.N. Epidemiologiya, techenie i osobennosti lecheniya tuberkuleza u bol’nyh VICH-infekciej. / Zimina V.N., Kravchenko A.V., Viktorova I.B. // Medicina v Kuzbasse. – 2011. – T. 3. – S. 6–13. (in Russian).
20. Viktorova I.B. Bakteriovydelenie u pacientov s VICH-infekciej i tuberkulezom / Viktorova I.B., Zimina V.N., Kravchenko A.V., Khanin A.L. // Epidemiologiya i infekcionnye bolezni. Aktual’nye voprosy. – 2018. – T. 3. – S. 35–40. (in Russian).
21. Morris A, Sciurba FC, Lebedeva IP, Githaiga A, Elliott WM, Hogg JC, et al. Association of chronic obstructive pulmonary disease severity and Pneumocystis colonization. Am J Respir Crit Care Med. 2004;170(4):408–13.
22. Schmidt JJ, Lueck C, Ziesing S, Stoll M, Haller H, Gottlieb J, et al. Clinical course, treatment and outcome of Pneumocystis pneumonia in immunocompromised adults: a retrospective analysis over 17 years. Crit Care. 2018;22(1):307.
23. Ermak T.N. Generalizovannyj pnevmocistoz s porazheniem kozhi pri VICH-infekcii / Ermak T.N., Laseeva M.G. // Infekcionnye bolezni. – 2017. – T. 4. – C. 91–94. (in Russian).
24. Kanne JP, Yandow DR, Meyer CA. Pneumocystis jiroveci pneumonia: High-resolution CT findings in patients with and without HIV infection. Am J Roentgenol. 2012;198(6):555–61.
25. Morris A, Crothers K, Beck JM, Huang L. An Official ATS Workshop Report: Emerging Issues and Current Controversies in HIV-Associated Pulmonary Diseases. Proc Am Thorac Soc. 2011;8(1):17–26.
26. Skelly MJ, Holzman RS, Merali S. S-Adenosylmethionine Levels in the Diagnosis of Pneumocystis carinii Pneumonia in Patients with HIV Infection. Clin Infect Dis. 2008;46(3):467– 71.
27. Li H, Huang H, He H. Successful treatment of severe Pneumocystis pneumonia in an immunosuppressed patient using caspofungin combined with clindamycin: A case report and literature review. BMC Pulm Med. 2016;16(1):1–6. doi: org/10.1186/s12890-016-0307-0
28. Nickel P, Schurmann M, Albrecht H, Schindler R, Budde K, Westhoff T, et al. Clindamycin-primaquine for pneumocystis jiroveci pneumonia in renal transplant patients. Infection. 2014 Dec;42(6):981–9.
29. Morris SR, Zhao M, Smith DM, Vargas M V., Little SJ, Gianella S. Longitudinal viral dynamics in semen during early HIV infection. Clin Infect Dis. 2017;64(4):428–34.
30. Udeze A, Odebisi-Omokanye M, Ajileye T. Cytomegalovirus infection among Human Immunodeficiency Virus (HIV) infected individuals on highly active anti-retroviral therapy in North-Central Nigeria. Afr Health Sci. 2018 Dec;18(4):1057– 65.
31. Shakhgil’dian V.I., Kliniko-laboratornaya harakteristika, patomorfologicheskie osobennosti, diagnostika i lechenie citomegalovirusnoj pnevmonii / Shakhgil’dian V.I., Tishkevich O.A., Shipulina O.Yu. // Infekcionnye bolezni. – 2004. – T. 2 N 1. – S. 73–80. (in Russian).
32. Hooks B, Abboud R. CMV Pneumonitis: A Rare and Infrequent Coinfection of Pneumonia in AIDS. Chest [Internet]. 2017 Oct 1;152(4):A170. [Cited 23.08.2019] Available from: https://doi.org/10.1016/j.chest.2017.08.201
33. Perez C, Garcia P, Calvo M, Labarca J, Bustos M, Beroiza T, et al. Etiology of pneumonia in chilean HIV-infected adult patients. Rev Chilena Infectol. 2011 Aug;28(4):343–8.
34. Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children. [Internet]. 2019 [Cited 31.07.2019] Available from: https://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf
35. Shakhgil’dian V.I. Struktura vtorichnyh zabolevanij i sovremennye pohody k ih laboratornoj diagnostike u bol’nyh VICH-infekciej / Shakhgil’dian V.I., Yadrikhinskaya M.C., Safonova A.P., Domonova E.A., Shipulina O.Yu., Al’vares Figeroa M.V., Dolgova E.A., Tishkevich O.A. // Epidemiologiya i infekcionnye bolezni Aktual’nye voprosy. – 2015/ – N1. – S. 24–30. (in Russian).
36. EL Fane M, Sodqi M, EL Rherbi A, Chakib A, Oulad Lahsen A, Marih L MEFK. Antimicrobial Agents Cytomegalovirus Disease in Patient with HIV Infection. J Antimicro. 2016;(1):108.
37. Soderberg-Naucler C. Treatment of cytomegalovirus infections beyond acute disease to improve human health. Expert Rev Anti Infect Ther. 2014 Feb;12(2):211–22.
38. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/ AIDS. AIDS. 2009 Feb;23(4):525–30.
39. Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM, et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017 Aug;17(8):873–81.
40. World Health Organization Rapid Advice: Diagnosis, Prevention and Management of Cryptococcal Disease in HIVInfected Adults, Adolescents and Children: December 2011 [Internet]. 2011 [Cited 20.08.2017] Available from: https://apps.who.int/iris/bitstream/handle/10665/44786/9789241502979_eng.pdf?sequence=1
41. Meyohas MC, Roux P, Bollens D, Chouaid C, Rozenbaum W, Meynard JL, et al. Pulmonary cryptococcosis: localized and disseminated infections in 27 patients with AIDS. Clin Infect Dis. 1995 Sep;21(3):628–33.
42. Antinori S. New Insights into HIV/AIDS-Associated Cryptococcosis. ISRN AIDS. 2013 Feb;2013:471363.
43. Colombo AL, Tobon A, Restrepo A, Queiroz-Telles F, Nucci M. Epidemiology of endemic systemic fungal infections in Latin America. Med Mycol. 2011 Nov;49(8):785–98.
44. Ashbee HR, Evans EG V, Viviani MA, Dupont B, Chryssanthou E, Surmont I, et al. Histoplasmosis in Europe: report on an epidemiological survey from the European Confederation of Medical Mycology Working Group. Med Mycol. 2008 Feb;46(1):57–65.
45. Adenis AA, Aznar C, Couppie P. Histoplasmosis in HIVInfected Patients: A Review of New Developments and Remaining Gaps. Vol. 1, Current tropical medicine reports. Switzerland; 2014. p. 119–28.
46. Hage CA, Ribes JA, Wengenack NL, Baddour LM, Assi M, McKinsey DS, et al. A multicenter evaluation of tests for diagnosis of histoplasmosis. Clin Infect Dis. 2011 Sep;53(5):448– 54.
47. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. [Internet]. 2019 p. 423. [Cited 15.07.2019]. Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. Accessed 5/24/2019.
48. Maheshwari M, Kaur R, Chadha S. Candida Species Prevalence Profile in HIV Seropositive Patients from a Major Tertiary Care Hospital in New Delhi, India. J Pathog. 2016;2016:6204804.
49. Roohani AH, Fatima N, Shameem M, Khan HM, Khan PA, Akhtar A. Comparing the profile of respiratory fungal pathogens amongst immunocompetent and immunocompromised hosts, their susceptibility pattern and correlation of various opportunistic respiratory fungal infections and their progression in relation to the CD4+T-c. Indian J Med Microbiol. 2018;36(3):408–15.
50. Kaur R, Mehra B, Dhakad MS, Goyal R, Bhalla P, Dewan R. Fungal Opportunistic Pneumonias in HIV/AIDS Patients: An Indian Tertiary Care Experience. J Clin Diagn Res. 2017 Feb;11(2):DC14–9.
51. Ito Y, Hirai T, Maekawa K, Fujita K, Imai S, Tatsumi S, et al. Predictors of 5-year mortality in pulmonary Mycobacterium avium-intracellulare complex disease. Int J Tuberc Lung Dis. 2012;16(3):408–14.
52. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175(4):367–416.
53. Panteleev A.M. Differencial’naya diagnostika tuberkuleza i mikobakterioza u bol’nyh VICH-infekciej / Panteleev A.M., Nikulina O.V., Khristusev A.S., Dracheva M.S., Sokolova O.S., Zonova A.V. // Tuberkulez i bolezni legkih. – 2017. – Vol. 95 N10. – S. 47–52. (in Russian).
54. Zimina V.N. Mikobakteriozy: sovremennoe sostoyanie problemy / Zimina V.N., Degtyareva S.Yu., Beloborodova E.N., Kulabukhova E.I., Rusakova L.I., Fesenko O.V. // 2017. – Vol. 19 N4. –S. 276–82. (in Russian).
55. Yangco BG, Buchacz K, Baker R, Palella FJ, Armon C, Brooks JT. Is primary mycobacterium avium complex prophylaxis necessary in patients with CD4
56. Society EAC. EACS Guidelines [Internet]. Version 9.1. [Cited 19.06.2019] Available from: http://www.eacsociety.org/files/2018_guidelines-9.1-english.pdf
57. Pokrovsky V.V. VICH-infekciya i SPID, klinicheskie rekomendacii / Belyaeva V.V., Ermak T.N., Zimina V.N., Kanestri V.G., Kozirina N.V., Kravchenko A.V., Pokrovsky V.V., Popova A.A., Shakhgil’dian V.I., Yurin O.G. // Epidemologiya i infekcionnye bolezni. – 2019. – T.6 . – 160 s. (in Russian).
58. Lawn SD, Wood R. Poor prognosis of HIV-associated tuberculous meningitis regardless of the timing of antiretroviral therapy. Vol. 52, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2011. p. 1384–7.
59. Boulware DR, Meya DB, Muzoora C, Rolfes MA, Huppler Hullsiek K, Musubire A, et al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med. 2014 Jun;370(26):2487–98.
Review
For citations:
Viktorova I.B., Zimina V.N., Degtyareva S.Yu., Kravtchenko A.V. Respiratory diseases in HIV-infected patients (review). Journal Infectology. 2020;12(4):5-18. (In Russ.) https://doi.org/10.22625/2072-6732-2020-12-4-5-18
Views:
2964
.png)
.png)
Email this article 